Griffiths, Elizabeth A.
Min, Jae S.
Lee, Wei-Nchih
Yu, Jeffrey C.
Patel, Yogesh
Myren, Karl-Johan
Dingli, David
Article History
Received: 27 February 2024
Accepted: 29 July 2024
First Online: 9 August 2024
Declarations
:
: The study protocol, informed consent form, recruitment materials and participant materials were reviewed and approved by the Western Institutional Review Board. All patients provided informed consent to participate in the study. Participation in the study was voluntary, and patients were free to withdraw at any time.
: Not required.
: Elizabeth A. Griffiths receives honoraria/grant support and/or has relationships with AbbVie, Alexion, AstraZeneca Rare Disease, American Society of Hematology, Apellis, The Aplastic Anemia and MDS International Foundation, Celgene/BMS, CTI BioPharma, Genentech, MediCom Worldwide, Novartis, Physician Educational Resource, PicnicHealth, Taiho Oncology, and Takeda Oncology. Jae S. Min was an employee of and owned stock options in Evidation Health, Inc. at the time of the study. Wei-Nchih Lee is an employee of and owns stock options in Evidation Health, Inc. Jeffrey C. Yu, Yogesh Patel and Karl-Johan Myren are employees of and shareholders in Alexion, AstraZeneca Rare Disease. David Dingli receives honoraria from Alexion, AstraZeneca Rare Disease, Apellis, GSK, Janssen, Novartis, Osseum, Roche, Sanofi, and Takeda.